# Study Switching HIV-1 Infected Patients With an Undetectable Viral Load on a First Protease Inhibitor-Based Regimen to an Efavirenz-Based Regimen

> **NCT00135382** · PHASE3 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 254 (—)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Videx EC
- **DRUG:** Epivir
- **DRUG:** Sustiva

## Key facts

- **NCT ID:** NCT00135382
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-06
- **Primary completion:** 2005-10
- **Final completion:** 2005-10
- **Target enrollment:** 254 (—)
- **Last updated:** 2010-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00135382

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00135382, "Study Switching HIV-1 Infected Patients With an Undetectable Viral Load on a First Protease Inhibitor-Based Regimen to an Efavirenz-Based Regimen". Retrieved via AI Analytics 2026-08-17 from https://api.ai-analytics.org/clinical/NCT00135382. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*